CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
Raltegravir +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01785160
NCT01785160Phase 1Completed

Investigation of Faldaprevir Effect on Steady State Pharmacokinetics of Raltegravir in Healthy Male and Female Volunteers (an Open-label Trial With Two Periods in a Fixed Sequence)

Boehringer Ingelheim·interventional·Posted Feb 7, 2013·Updated Aug 3, 2015

In Brief

A Phase 1 clinical trial evaluating Raltegravir and Faldaprevir for Healthy. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The primary objective of this trial is to investigate effect of faldaprevir on steady state pharmacokinetics of raltegravir. The assessment of safety and tolerability will be an additional objective of this trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 7, 2013
Enrollment StartFeb 1, 2013
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.4 years ago

Interventions

Raltegravirdrug

low dose oral administration

Raltegravirdrug

low dose oral administration

Faldaprevirdrug

medium dose oral administration